Vanta Bioscience Fair Value
Fair Value Analysis Export
P/B Based Valuation
Asset-Based Valuation
VANTABIO Fair Value Analysis — Data Sources & Coverage
Vanta Bioscience financial data sources, valuation methods applied and sector benchmarks used — 2023 financial year. Check VANTABIO company valuation to track the company's total market size over time.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is 3 years old (2023).
VANTABIO vs Healthcare Sector Peers — P/E, P/B & Market Cap
Vanta Bioscience P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Divis Laboratories | DIVISLAB | 84.36 | 14.72 | ₹244,125 |
| Syngene International | SYNGENE | 65.37 | 2.98 | ₹14,538 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Sat Kartar Life | SATKARTAR | 15.4 | 3.85 | ₹252 |
| Cohance Lifesciences | COHANCE | 291.99 | 4.37 | ₹17,485 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.